Genovis AB (publ.) Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Genovis AB (publ.) wird ein jährliches Gewinn- und Umsatzwachstum von 13.6% bzw. 19.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 19.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18% betragen.
Wichtige Informationen
28.8%
Wachstumsrate der Gewinne
31.3%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 48.6% |
| Wachstumsrate der Einnahmen | 15.5% |
| Zukünftige Eigenkapitalrendite | 14.5% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 22 Aug 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts
Aug 23
Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models
Apr 26Recent updates
Genovis AB (publ.)'s (STO:GENO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Sep 19Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings
Aug 28Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts
Aug 23The Genovis AB (publ.) (STO:GENO) Analysts Have Been Trimming Their Sales Forecasts
Aug 21Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Aug 12Genovis AB (publ.)'s (STO:GENO) 36% Jump Shows Its Popularity With Investors
May 31This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate
May 09Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models
Apr 26Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Mar 18What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash
Feb 28We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings
Feb 22These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts
Feb 20Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be
Feb 04Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors
Oct 06Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?
Jun 22What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?
May 13Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?
Dec 22Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?
Nov 14If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity
Jul 08Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?
Jun 01Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%
May 10One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically
Feb 10Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?
Aug 09What Is Genovis AB (publ.)'s (STO:GENO) Share Price Doing?
Mar 27Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 183 | 39 | 36 | 50 | 3 |
| 12/31/2025 | 152 | 35 | 28 | 33 | 3 |
| 12/31/2024 | 129 | 28 | 27 | 50 | 3 |
| 6/30/2024 | 128 | 17 | 27 | 37 | N/A |
| 3/31/2024 | 128 | 31 | 27 | 39 | N/A |
| 12/31/2023 | 159 | 62 | 55 | 68 | N/A |
| 9/30/2023 | 158 | 54 | 40 | 53 | N/A |
| 6/30/2023 | 151 | 57 | 40 | 49 | N/A |
| 3/31/2023 | 142 | 42 | 42 | 47 | N/A |
| 12/31/2022 | 104 | 11 | -5 | -1 | N/A |
| 9/30/2022 | 119 | 41 | 40 | 43 | N/A |
| 6/30/2022 | 112 | 36 | 40 | 43 | N/A |
| 3/31/2022 | 111 | 36 | 37 | 41 | N/A |
| 12/31/2021 | 94 | 25 | 41 | 46 | N/A |
| 9/30/2021 | 71 | 11 | 3 | 6 | N/A |
| 6/30/2021 | 69 | 12 | 1 | 7 | N/A |
| 3/31/2021 | 65 | 9 | -12 | 9 | N/A |
| 12/31/2020 | 61 | 6 | -17 | 4 | N/A |
| 9/30/2020 | 54 | -3 | -16 | 7 | N/A |
| 6/30/2020 | 64 | 3 | -11 | 9 | N/A |
| 3/31/2020 | 60 | 6 | 4 | 9 | N/A |
| 12/31/2019 | 61 | 10 | 8 | 13 | N/A |
| 9/30/2019 | 58 | 12 | 7 | 10 | N/A |
| 6/30/2019 | 43 | 5 | 0 | 4 | N/A |
| 3/31/2019 | 40 | 1 | 2 | 3 | N/A |
| 12/31/2018 | 35 | -2 | -3 | -1 | N/A |
| 9/30/2018 | 31 | -4 | -4 | -2 | N/A |
| 6/30/2018 | 27 | -6 | -6 | -5 | N/A |
| 3/31/2018 | 24 | -7 | N/A | -9 | N/A |
| 12/31/2017 | 23 | -8 | N/A | -8 | N/A |
| 9/30/2017 | 21 | -9 | N/A | -9 | N/A |
| 6/30/2017 | 21 | -9 | N/A | -11 | N/A |
| 3/31/2017 | 20 | -14 | N/A | -15 | N/A |
| 12/31/2016 | 19 | -15 | N/A | -16 | N/A |
| 9/30/2016 | 17 | -16 | N/A | -18 | N/A |
| 6/30/2016 | 16 | -21 | N/A | -18 | N/A |
| 3/31/2016 | 14 | -18 | N/A | -14 | N/A |
| 12/31/2015 | 14 | -20 | N/A | -16 | N/A |
| 9/30/2015 | 13 | -25 | N/A | -18 | N/A |
| 6/30/2015 | 11 | -24 | N/A | -20 | N/A |
| 3/31/2015 | 10 | -23 | N/A | -21 | N/A |
| 12/31/2014 | 10 | -22 | N/A | -22 | N/A |
| 9/30/2014 | 8 | -20 | N/A | -18 | N/A |
| 6/30/2014 | 10 | -17 | N/A | -17 | N/A |
| 3/31/2014 | 11 | -16 | N/A | -14 | N/A |
| 12/31/2013 | 10 | -16 | N/A | -12 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: GENODas prognostizierte Gewinnwachstum (13.6% pro Jahr) liegt über der Sparquote (1%).
Ertrag vs. Markt: GENODie Erträge des Unternehmens (31.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (16.1% pro Jahr).
Hohe Wachstumserträge: GENOEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: GENODie Einnahmen des Unternehmens (19.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.9% pro Jahr).
Hohe Wachstumseinnahmen: GENODie Einnahmen des Unternehmens (15.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: GENODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18%).